查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1870759

貓過敏治療市場按產品類型、研發階段、給藥途徑、治療方法和分銷管道分類－2025-2032年全球預測

Cat Allergy Pipeline Market by Product Type, Stage Of Development, Route Of Administration, Therapy Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，貓過敏治療市場將成長至 71.3 億美元，複合年成長率為 5.86%。

關鍵市場統計數據
基準年 2024 45.2億美元
預計年份：2025年 47.9億美元
預測年份 2032 71.3億美元
複合年成長率 (%) 5.86%

為策略決策者提供影響貓過敏治療領域的科學、臨床和商業性趨勢的全面概述

本執行摘要簡明扼要地概述了貓過敏治療領域不斷發展的治療模式。它重點關注對價值鏈上相關人員至關重要的科學創新、臨床進展和商業化考量。概述整合了生物製藥和免疫療法的最新進展、不斷變化的法規環境，以及對產品開發團隊、商業負責人和生產合作夥伴的戰術性影響。透過將新興治療方法與傳統治療路徑進行對比，本概要突顯了治療方法差異化能夠對臨床應用和支付方參與產生最大影響的領域。

標靶免疫調節、適應性臨床設計和製造創新的進展如何從整體上重塑貓過敏治療策略

貓過敏的治療模式正從漸進式症狀管理轉向標靶免疫調節和精準醫療，將對研發、臨床實踐和支付系統產生變革性影響。單株抗體工程和重組蛋白平台的進步提高了特異性和安全性的標準，而新型疫苗構建體和基於胜肽的免疫療法正在重新定義持久性緩解疾病的概念。因此，研發人員越來越重視那些既能緩解急性症狀又能長期調節過敏原特異性免疫反應的機制。

評估2025年關稅政策如何重塑貓過敏計畫的供應鏈韌性、製造在地化策略和採購優先事項

2025年關稅的累積影響正在衝擊著研發和開發平臺貓過敏治療藥物的開發商和契約製造製造商的供應鏈、籌資策略和成本結構。關鍵原料、耗材和專用設備的進口成本不斷上漲，增加了生產計畫的壓力，迫使研發公司加快步伐，確保多通路供應並對沖庫存風險。因此，採購部門正積極協商長期供應協議，並尋找其他區域供應來源，以維持複雜生物製藥流程的連續性。

將產品模式、研發里程碑、給藥途徑、治療目的和分銷管道與商業化策略聯繫起來的詳細細分分析

細分市場趨勢揭示了科學創新與商業性機會在產品類型、研發階段、給藥途徑、治療目標和分銷策略等方面的交匯點。在產品類型方面，單株抗體持續發展，高度人源化和全人源化構建體旨在最大限度地降低免疫抗原性並延長給藥間隔，而嵌合體製劑仍然適用於基於特定機制的適應症。重組蛋白包括過敏原特異性免疫療法和融合蛋白，其目標是透過靶向免疫調節而非簡單的症狀緩解來誘導免疫耐受性。小分子療法，例如組織胺受體拮抗劑和白三烯抑制劑，在急性症狀管理和聯合治療中繼續發揮補充作用。疫苗方法涵蓋過敏原萃取物疫苗、DNA平台和胜肽疫苗，旨在透過抗原特異性暴露實現持續的免疫重編程。

影響美洲、歐洲、中東和非洲以及亞太地區發展、准入和商業化路徑的區域趨勢和戰略要務

區域趨勢在全球範圍內對研發重點、監管互動和商業化路徑的影響各不相同。在美洲，完善的臨床試驗基礎設施和以支付主導的證據要求有利於那些將明確的臨床差異化與真實世界數據計劃相結合的項目。研發方通常會利用龐大且多樣化的患者群體進行註冊試驗，同時儘早與支付方就對報銷至關重要的療效指標達成協議。歐洲、中東和非洲（EMEA）的監管環境複雜多元，既有集中式監管路徑，也有國家級監管路徑。這迫使申辦方採用模組化的監管策略，並投資於區域諮詢服務，以滿足區域臨床和定價方面的預期。此外，EMEA市場往往更注重長期價值和比較療效，這會影響試驗設計和核准後證據的產生。

生物製藥公司、生技公司和生產合作夥伴之間的策略行動和能力差異決定了它們在貓過敏藥物研發管線中的主導。

主要企業的動態特性揭示了組織策略和能力組合如何影響其在貓過敏領域的競爭地位。主導的生物製藥公司透過在抗體工程、重組表達系統和專有抗原庫方面的平台投資來實現差異化，而敏捷的生物技術公司則利用其在特定作用機制領域的專長和快速的概念驗證（PoC）執行能力。合約開發和生產組織（CDMO）正在擴展其生物製藥生產能力，提供端到端的模組化解決方案，在不犧牲品管的前提下加快臨床試驗進程，從而改變了企業在內部生產和外包之間的選擇。

一份切實可行的策略藍圖，旨在整合生物標記主導的研發、供應鏈韌性和精準商業化，從而最大限度地提高研發管線的成功率。

產業領導者應採取整合科學差異化、營運韌性和市場進入規劃的策略，將研發管線進展轉化為持續的臨床影響。首先，應優先投資於機制驅動型生物標記和患者分層工具，以提高獲得明確臨床訊號的機率並簡化監管互動。同時，應確保供應管道多元化，並考慮建立區域性生產夥伴關係，以降低地緣政治和關稅相關干擾的影響，同時確保臨床試驗按計劃進行。雙管齊下地專注於證據生成和供應韌性，將有助於降低專案風險，並增強與支付方和採購合作夥伴的談判能力。

結合專家訪談、流程圖繪製和多學科檢驗的穩健混合方法研究途徑，確保了可靠的洞察和可操作的研究結果。

為確保研究結果的可靠性和可追溯性，本研究採用混合方法，結合了初步質性研究和結構化的二次分析。初步研究包括對臨床研究人員、法規事務專業人員、生產主管和商業化負責人進行訪談，以收集關於研究設計、監管預期和供應鏈限制的第一手觀點。這些第一手見解與研究註冊庫、已發布的監管指南、專利概況和科學文獻的系統性回顧相結合，以檢驗機制論點並識別不同項目之間的通用主題。

策略結論綜合分析，重點闡述了貓過敏藥物領域中科學創新、營運韌性和市場進入要求的融合。

總之，貓過敏藥物開發平臺正處於一個轉折點，科學進步、適應性臨床方法和商業需求的融合，為研發人員創造了新的機遇，同時也帶來了更高的複雜性。抗體設計、重組平台和疫苗技術的創新正在拓展治療工具箱，而日益精細的試驗設計和證據策略則提高了臨床價值提案的清晰度。同時，關稅趨勢和區域監管差異等外部因素凸顯了製定穩健的供應策略和針對特定區域的市場進入計畫的必要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在 III 期臨床試驗中整合重組 Fel d 1 低過敏性貓疫苗，以擴大免疫治療選擇範圍
  • 利用標靶 Fel d 1 過敏原表位的單株抗體療法進行精準症狀控制
  • 利用重組貓過敏原肽開發舌下免疫療法製劑以提高安全性
  • 攜帶式生物標記診斷檢測技術的進步，可用於即時監測貓過敏的嚴重程度和治療效果
  • 生技公司與學術機構的策略合作加速了貓過敏疫苗的開發平臺。
  • 利用CRISPR基因編輯技術降低家貓體內Fel d 1的表達，進而預防長期過敏症
  • 透過區域協調法規結構，簡化新型貓過敏生物療法的核准流程
  • 針對重點市場的下一代貓過敏免疫療法的商業化和患者依從性策略

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型分類的貓過敏治療市場

  • 單株抗體
    • 嵌合體體
    • 完全人類
    • 人性化
  • 重組蛋白
    • 過敏原特異性免疫療法
    • 融合蛋白
  • 小分子療法
    • 組織胺受體拮抗劑
    • 白三烯抑制劑
  • 疫苗
    • 過敏原萃取疫苗
    • DNA疫苗
    • 胜肽疫苗

第9章 貓過敏治療市場依發展階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前階段
  • 監管部門核准

第10章 依給藥途徑分類的貓過敏治療市場

  • 靜脈注射
  • 口服
  • 皮下注射
  • 局部用藥

第11章 貓過敏治療市場（依治療方法）

  • 預防
  • 治療

第12章 貓過敏治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科診所

第13章 各地區貓過敏治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 貓過敏治療市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國貓過敏治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • ALK-Abello A/S
    • Stallergenes Greer SA
    • Circassia Pharmaceuticals PLC
    • Allergy Therapeutics PLC
    • DBV Technologies SA
    • Bencard Allergie GmbH
    • HAL Allergy BV
    • LETI Pharma SL
    • Inmunotek SA
    • Viatris Inc.
Product Code: MRR-1A1A064C0355

The Cat Allergy Pipeline Market is projected to grow by USD 7.13 billion at a CAGR of 5.86% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.52 billion
Estimated Year [2025] USD 4.79 billion
Forecast Year [2032] USD 7.13 billion
CAGR (%) 5.86%

Comprehensive orientation to the scientific, clinical, and commercial dynamics shaping the cat allergy therapeutic landscape for strategic decision-makers

This executive summary offers a concise yet comprehensive orientation to the evolving therapeutic landscape for cat allergy, focusing on scientific innovation, clinical progression, and commercialization considerations that matter to stakeholders across the value chain. The overview synthesizes recent advances in biologics and immunotherapies, the shifting regulatory environment, and the tactical implications for product development teams, commercial leaders, and manufacturing partners. By situating emerging modalities alongside legacy care pathways, the narrative clarifies where therapeutic differentiation is most likely to influence clinical adoption and payer engagement.

Throughout the document, we emphasize actionable intelligence drawn from clinical trial registries, regulatory guidance trends, manufacturing capacity signals, and stakeholder interviews. Consequently, readers will gain a clear sense of which mechanisms of action and delivery technologies are gaining traction, how development timelines are affected by regulatory scrutiny, and where strategic partnerships can de-risk development and accelerate access. In short, this introduction frames the core opportunities and constraints that must be navigated to convert scientific promise into accessible therapies for patients affected by cat allergy.

How advances in targeted immunomodulation, adaptive clinical design, and manufacturing innovations are collectively reshaping therapeutic strategies in cat allergy

The cat allergy landscape has shifted from incremental symptom management toward targeted immunomodulation and precision approaches, generating transformative implications for R&D, clinical practice, and payer frameworks. Advances in monoclonal antibody engineering and recombinant protein platforms have raised the bar for specificity and safety, while novel vaccine constructs and peptide-based immunotherapies are redefining the notion of durable disease modification. As a result, developers are increasingly prioritizing mechanisms that offer both acute symptom relief and long-term modulation of allergen-specific immune responses.

Concurrently, clinical trial design has adapted to these scientific shifts by emphasizing patient-reported outcomes, biomarker-driven endpoints, and adaptive protocols to accelerate go/no-go decisions. This evolution reduces reliance on broad symptom scores and instead targets mechanistic readouts that predict sustained efficacy. In addition, manufacturing technologies such as single-use bioreactors and advances in purification have compressed time-to-clinic for biologics, enabling nimble iterative development. Taken together, these transformative shifts are reshaping competitive dynamics, making strategic alliances, and platform investments pivotal for organizations seeking leadership in the cat allergy domain.

Assessment of how 2025 tariff policies have reshaped supply chain resilience, manufacturing localization strategies, and procurement priorities for cat allergy programs

The cumulative impact of tariff measures enacted in 2025 has reverberated across supply chains, procurement strategies, and cost structures for developers and contract manufacturers servicing the cat allergy pipeline. Increased import costs for critical raw materials, consumables, and specialized equipment intensified pressure on production planning, prompting sponsors to secure multi-sourced supply arrangements and to accelerate inventory hedging. Consequently, procurement teams have become more active in negotiating long-term supplier commitments and in qualifying alternate regional sources to preserve continuity for complex biologic processes.

In parallel, tariffs amplified the importance of domestic manufacturing capacity in certain jurisdictions, encouraging sponsors to evaluate regional manufacturing partnerships and technology transfers to mitigate exposure. Regulatory agencies and contract manufacturing organizations responded by clarifying import documentation requirements and by offering guidance on localized quality oversight, which in turn raised the operational bar for global programs. Furthermore, payers and procurement stakeholders signaled heightened scrutiny over total cost of therapy, motivating developers to identify formulation or delivery optimizations that reduce downstream dispensing and administration costs. Ultimately, the 2025 tariff environment accelerated structural shifts toward more resilient, regionally diversified supply models and fostered strategic decisions aimed at preserving clinical timelines while managing incremental cost pressures.

In-depth segmentation analysis linking product modalities, development milestones, administration routes, therapy intent, and distribution channels to commercialization strategy

Segment-specific dynamics reveal where scientific innovation and commercial opportunity intersect across product type, development stage, route of administration, therapy intent, and distribution strategy. Within product type, monoclonal antibodies are advancing with increasingly humanized and fully human constructs designed to minimize immunogenicity and extend dosing intervals, while chimeric formats remain relevant for certain mechanism-driven indications. Recombinant proteins encompass allergen specific immunotherapies and fusion proteins that leverage targeted immune modulation to induce tolerance rather than simple symptomatic relief. Small molecule therapies, including histamine receptor antagonists and leukotriene inhibitors, continue to play complementary roles in acute symptom control and in combination regimens. Vaccine approaches span allergen extract vaccines, DNA platforms, and peptide vaccines that aim to drive durable immune reprogramming through antigen-specific exposure.

Regarding stage of development, programs in preclinical and early-phase stages are refining translational biomarkers to de-risk later-stage trials, while Phase II and Phase III assets are increasingly integrating enriched patient populations and mechanistic endpoints to strengthen regulatory submissions. Route of administration considerations, from intravenous to oral, subcutaneous, and topical formats, shape both patient adoption and delivery economics, with subcutaneous and oral approaches offering advantages in outpatient settings and topical modalities opening possibilities for localized immunomodulation. The distinction between prophylactic and therapeutic therapy types underscores divergent development strategies: prophylactic candidates emphasize safety and long-term immune memory, whereas therapeutic products prioritize rapid symptom control and measurable clinical improvement. Distribution channels likewise influence commercialization planning; hospital pharmacies and specialty clinics remain central for administration-intensive biologics, retail pharmacies support broad outpatient access for small molecules and injectables, and online pharmacies are increasingly relevant for chronic self-administered therapies. These segmentation lenses collectively inform prioritization of clinical endpoints, manufacturing scale-up pathways, and go-to-market models for developers targeting the cat allergy space.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence development, access, and commercialization pathways

Regional dynamics shape development priorities, regulatory interactions, and commercialization pathways in distinct ways across the globe. In the Americas, robust clinical trial infrastructure and payor-driven evidence requirements favor programs that pair clear clinical differentiation with real-world data plans; developers often leverage large, diverse patient cohorts for registrational studies while engaging payers early to align on outcomes that matter for reimbursement. Europe, Middle East & Africa presents a heterogeneous regulatory landscape where centralized and national pathways coexist, prompting sponsors to adopt modular regulatory strategies and to invest in regional advisory engagements to address varying clinical and pricing expectations. In addition, EMEA markets often prioritize long-term value and comparative effectiveness, which influences trial design and post-authorization evidence generation.

Meanwhile, the Asia-Pacific region is characterized by rapidly expanding research capabilities, increasing local manufacturing capacity, and a strong appetite for innovative therapeutics. Several countries in the region are streamlining regulatory reviews and fostering partnerships with global developers to expedite access. At the same time, regional differences in healthcare delivery models and reimbursement frameworks require tailored market access strategies. Taken together, these geographic considerations compel sponsors to align clinical development plans, manufacturing footprints, and value demonstration efforts with the specific regulatory, commercial, and patient-access dynamics of each region.

Strategic behaviors and capability differentiators among biopharma, biotech, and manufacturing partners that determine leadership potential in the cat allergy pipeline

Key company behaviors reveal how organizational strategy and capability sets influence competitive positioning within the cat allergy ecosystem. Leading biopharma sponsors are differentiating through platform investments in antibody engineering, recombinant expression systems, and proprietary antigen libraries, while nimble biotech firms are capitalizing on focused mechanism-of-action niches and rapid proof-of-concept execution. Contract development and manufacturing organizations have scaled biologics capabilities and are offering end-to-end modular solutions that allow innovators to compress time-to-clinic without sacrificing quality control, thereby changing the calculus for in-house versus outsourced production.

Moreover, strategic partnerships, licensing deals, and co-development arrangements are central to de-risking late-stage programs and to expanding global reach. Companies that integrate clinical, regulatory, and commercial expertise early in development tend to navigate complex approval pathways and payer dialogues more effectively. At the same time, investments in cold chain logistics and specialized delivery formats have become differentiators for firms seeking broad international distribution. Ultimately, organizations that demonstrate agility in trial execution, robustness in manufacturing scale-up, and clarity in value communication are best positioned to convert pipeline promise into clinical and commercial outcomes.

Actionable strategic blueprint for leaders to align biomarker-driven development, supply resilience, and targeted commercialization to maximize pipeline success

Industry leaders should adopt an integrated strategy that aligns scientific differentiation with operational resilience and market access planning to convert pipeline advances into sustained clinical impact. First, prioritize early investment in mechanistic biomarkers and patient stratification tools to increase the probability of clear clinical signals and to streamline regulatory engagement. Concurrently, secure diversified supply options and consider regional manufacturing partnerships to mitigate geopolitical and tariff-related disruptions while preserving clinical timelines. This dual emphasis on evidence generation and supply resilience reduces program risk and enhances negotiating leverage with payers and procurement partners.

Next, design commercialization pathways that match route-of-administration advantages to distribution channels, ensuring administration-intensive biologics are supported by specialty clinic networks while self-administered formulations are optimized for retail and online pharmacy channels. Additionally, cultivate strategic alliances that bring complementary capabilities-such as formulation expertise, regional regulatory know-how, and real-world evidence generation-so that development programs can scale efficiently. Finally, embed clear value demonstration plans that anticipate payer expectations around comparative effectiveness and long-term outcomes, and prepare post-authorization evidence programs to sustain access and uptake. By executing these coordinated actions, industry leaders can translate R&D momentum into durable commercial success and improved patient outcomes.

Robust mixed-methods research approach combining expert interviews, pipeline mapping, and multi-source triangulation to ensure high-confidence insights and actionable findings

This research applied a mixed-methods approach combining primary qualitative inquiry with structured secondary analysis to ensure robustness and traceability of insights. Primary research consisted of interviews with clinical investigators, regulatory affairs specialists, manufacturing executives, and commercialization leads to capture frontline perspectives on trial design, regulatory expectations, and supply chain constraints. These firsthand inputs were synthesized with structured reviews of trial registries, publicly available regulatory guidance, patent landscapes, and scientific literature to validate mechanistic claims and to identify recurring themes across programs.

Analytical methods included pipeline mapping to reconcile stage-of-development classifications, cross-validation of administration routes and formulation strategies, and assessment of distribution pathways against real-world delivery constraints. Data quality was assured through triangulation across multiple independent sources and through internal consistency checks. In addition, the research team applied scenario analysis techniques to explore how external shocks-such as tariff changes and regional regulatory shifts-interact with operational choices. This layered methodology produced an evidence-based narrative that balances empirical observation with expert interpretation, designed to inform both strategic planning and operational execution.

Synthesis of strategic conclusions emphasizing the convergence of scientific innovation, operational resilience, and market access imperatives for cat allergy therapeutics

In conclusion, the cat allergy pipeline is at an inflection point where scientific advances, adaptive clinical approaches, and operational imperatives converge to create new opportunities and heightened complexity for developers. Innovations in antibody design, recombinant platforms, and vaccine technologies are expanding the therapeutic toolkit, while increasingly sophisticated trial design and evidence strategies improve the clarity of clinical value propositions. At the same time, external forces such as tariff dynamics and regional regulatory variability underscore the need for resilient supply strategies and region-specific market access planning.

Therefore, stakeholders who pair rigorous biomarker-driven development with strategic manufacturing and distribution decisions will be best positioned to navigate regulatory expectations and payer requirements. By adopting a coordinated approach that spans early clinical development through commercialization, organizations can accelerate meaningful patient benefit while managing programmatic risk. The insights contained in this report provide a strategic foundation for those seeking to make informed investments, pursue partnerships, and operationalize plans that respond to the rapidly evolving landscape of cat allergy therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of recombinant Fel d 1 hypoallergenic cat vaccines in phase III trials to expand immunotherapy options
  • 5.2. Emergence of monoclonal antibody therapies targeting Fel d 1 allergen epitopes for precision symptom control
  • 5.3. Development of sublingual immunotherapy formulations using recombinant cat allergen peptides to improve safety profiles
  • 5.4. Advancements in portable biomarker diagnostic assays for real-time monitoring of cat allergy severity and treatment efficacy
  • 5.5. Strategic collaborations between biotech firms and academic institutions to accelerate cat allergy vaccine pipelines
  • 5.6. Application of CRISPR gene editing to reduce Fel d 1 expression in domestic cats for long-term allergy prophylaxis
  • 5.7. Harmonization of regulatory frameworks across regions to streamline approval of novel cat allergy biologic treatments
  • 5.8. Commercial launch and patient adherence strategies for next-generation cat allergy immunotherapeutics in key markets

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cat Allergy Pipeline Market, by Product Type

  • 8.1. Monoclonal Antibodies
    • 8.1.1. Chimeric
    • 8.1.2. Fully Human
    • 8.1.3. Humanized
  • 8.2. Recombinant Proteins
    • 8.2.1. Allergen Specific Immunotherapies
    • 8.2.2. Fusion Proteins
  • 8.3. Small Molecule Therapies
    • 8.3.1. Histamine Receptor Antagonists
    • 8.3.2. Leukotriene Inhibitors
  • 8.4. Vaccines
    • 8.4.1. Allergen Extract Vaccines
    • 8.4.2. Dna Vaccines
    • 8.4.3. Peptide Vaccines

9. Cat Allergy Pipeline Market, by Stage Of Development

  • 9.1. Phase I
  • 9.2. Phase Ii
  • 9.3. Phase Iii
  • 9.4. Preclinical
  • 9.5. Regulatory Approval

10. Cat Allergy Pipeline Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous
  • 10.4. Topical

11. Cat Allergy Pipeline Market, by Therapy Type

  • 11.1. Prophylactic
  • 11.2. Therapeutic

12. Cat Allergy Pipeline Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
  • 12.4. Specialty Clinics

13. Cat Allergy Pipeline Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cat Allergy Pipeline Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cat Allergy Pipeline Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. ALK-Abello A/S
    • 16.3.2. Stallergenes Greer SA
    • 16.3.3. Circassia Pharmaceuticals PLC
    • 16.3.4. Allergy Therapeutics PLC
    • 16.3.5. DBV Technologies SA
    • 16.3.6. Bencard Allergie GmbH
    • 16.3.7. HAL Allergy BV
    • 16.3.8. LETI Pharma SL
    • 16.3.9. Inmunotek SA
    • 16.3.10. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CAT ALLERGY PIPELINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CAT ALLERGY PIPELINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CAT ALLERGY PIPELINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN SPECIFIC IMMUNOTHERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN SPECIFIC IMMUNOTHERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN SPECIFIC IMMUNOTHERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN SPECIFIC IMMUNOTHERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN SPECIFIC IMMUNOTHERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN SPECIFIC IMMUNOTHERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HISTAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HISTAMINE RECEPTOR ANTAGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HISTAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HISTAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HISTAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HISTAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY LEUKOTRIENE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN EXTRACT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN EXTRACT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN EXTRACT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN EXTRACT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN EXTRACT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ALLERGEN EXTRACT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE I, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE I, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE I, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE I, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE II, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE II, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE II, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE II, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE III, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE III, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE III, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PHASE III, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRECLINICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRECLINICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGULATORY APPROVAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGULATORY APPROVAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGULATORY APPROVAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGULATORY APPROVAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGULATORY APPROVAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGULATORY APPROVAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CAT ALLERGY PIPELINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE CAT ALLERGY PIPELINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY SMALL MOLECULE THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY STAGE OF DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST CAT ALLERGY PIPELINE MARKET SIZE, BY ROUTE